BOLDTIL™ CV

Cefuroxime 500mg + Clavulanic Acid 125mg represents a premium, broad-spectrum oral combination targeting both gram-positive and gram-negative resistant organisms through the synergy of a second-generation cephalosporin and a beta-lactamase inhibitor.

Cefuroxime (500mg) binds PBP1 and PBP2 on the bacterial membrane, blocking peptidoglycan transpeptidation. As a second-generation cephalosporin, it retains strong gram-positive activity (S. pneumoniae, S. pyogenes, MSSA) while extending gram-negative coverage to include H. influenzae, M. catarrhalis, E. coli, Klebsiella, and Proteus. Its prodrug form (cefuroxime axetil) is hydrolysed post-absorption to release active cefuroxime, with food significantly enhancing bioavailability.

Clavulanic Acid (125mg) irreversibly inhibits beta-lactamase enzymes, protecting cefuroxime from inactivation by beta-lactamase-producing organisms — particularly beta-lactamase-producing H. influenzae and M. catarrhalis (the primary cause of ENT antibiotic treatment failures), MSSA, and certain gram-negative resistant strains.

The unique clinical positioning of cefuroxime-clavulanate versus other cephalosporin-clavulanate combinations: cefuroxime's superior gram-positive spectrum (versus cefixime) combined with clavulanate's beta-lactamase protection creates the broadest gram-positive and gram-negative oral coverage of any cephalosporin combination — approaching the spectrum of parenteral second-generation beta-lactam combinations.

BOLDTIL™ CV is positioned as a premium, step-up oral antibiotic for moderate-to-severe community infections where both gram-positive and gram-negative beta-lactamase-producing organisms must be covered simultaneously.

ENT Infections (Primary): Severe or recurrent acute otitis media, chronic suppurative otitis media, complicated sinusitis, and peritonsillar abscess. Cefuroxime-clavulanate provides the most comprehensive ENT pathogen coverage of any oral cephalosporin combination — covering both MSSA (missed by cefixime-based combinations) and beta-lactamase-producing gram-negative ENT organisms.

Community-Acquired Pneumonia: Moderate severity CAP requiring gram-positive (including MRSP) AND gram-negative H. influenzae coverage with beta-lactamase protection — cefuroxime-clavulanate covers the complete CAP pathogen spectrum in a single oral tablet.

Skin and Soft Tissue Infections: Moderate cellulitis, wound infections, and animal bites — cefuroxime-clavulanate's MSSA + streptococcal + gram-negative coverage addresses the polymicrobial nature of most skin and wound infections.

Urinary Tract Infections: Complicated UTIs with beta-lactamase-producing gram-negative organisms.

Gynaecological Infections: Complicated PID and post-procedural infections with mixed aerobic flora.

Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.